Protocol Ledger

NCT06950385 · Phase III · RECRUITING

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

Interventional Phase III clinical trial protocol NCT06950385 sponsored by Rapamycin Holdings in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-18 Enrollment: 168 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06950385
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06950385
Protocol FieldVerified Registry Value
NCT IdentifierNCT06950385
Consolidated Lead SponsorRapamycin Holdings
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment168 participants (ESTIMATED)
Registered Start Date2025-07-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI